drugset / Trial / NCT00148421

Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.

NCT00148421 ↗

Phase 3 Completed Amgen
RandomizedParallel-groupOpen-labelTreatment

Summary

Comparing two drugs to treat subjects with non-myeloid malignancies receiving multicycle chemotherapy.

Timeline

Start
—
Primary completion
—
Completion
—

Outcome

Met primary endpoint

paper noninferiority was concluded because the upper 95% CI limit of the difference between groups (10.8%) was below the prespecified noninferiority margin. PMID 16710026 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic 200 ug —
Subject epoetin alfa Protein / enzyme biologic 40000 iu —

Indications